Wingor closely follows the "dual-track" regulatory framework for cell therapy in my country, focusing on innovative biopharmaceutical applications as its primary strategy. Simultaneously, it collaborates with top-tier tertiary hospitals in China to implement clinical research projects on new biopharmaceutical technologies. The company has established long-term strategic partnerships with over 80 tertiary hospitals nationwide, accumulating clinical protocols and extensive research experience covering more than 40 single diseases in key areas such as neurological and degenerative diseases, with tens of thousands of cases accumulated. Currently, five clinical research projects are underway, and the company is also undertaking a key national project for the 14th and 15th Five-Year Plan period.

Based on its extensive R&D and clinical experience, Inglos Biotech provides partner hospitals with support from R&D and preparation to clinical research, aiming to ensure the scientific and efficient nature of clinical research and accelerate the transformation and application of research results.